Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday

What happened

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) were up more than 67% Monday afternoon as of 2 p.m. ET after jumping as much as 102% three minutes after the opening bell. The company's shares climbed after it reported positive phase 2 trial results at its research and development day on Monday, before the markets opened. The stock is up more than 306% this year.

So what

MoonLake is a clinical-stage biotech company that focuses on treating inflammatory diseases. The company said that its phase 2 trial for nanobody sonelokimab met its primary endpoints for efficacy and safety in a phase 2 trial to treat patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin condition. According to MoonLake, the trials show that sonelokimab has the potential to be a best-in-class therapy for HS, as it has shown superior effectiveness, compared to Bimekizumab (bimzelx), a therapy manufactured by Belgian biopharmaceutical UCB SA.

Now what

MoonLake said that the HS market is worth $10 billion, so the therapy, if approved, could be lucrative for MoonLake. The 24-week results of the trial should be ready by the fourth quarter. Sonelokimab is also being tested in a phase 2 trial to treat active psoriatic arthritis (PsA).

It's important to note that the company doesn't have any approved therapies and has a lot riding on sonelokimab. The therapy is a nanobody, which consists of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies are known for their small size, giving them an advantage in tissue penetration.

MoonLake, in its first-quarter report, said it had $63.1 million in cash, enough to fund operations into the end of 2024, according to Chief Financial Officer Matthias Bodenstedt. Considering the huge run-up in the stock's price, it wouldn't be surprising to see the price drop soon, as some investors will take profits.

10 stocks we like better than MoonLake Immunotherapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and MoonLake Immunotherapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 26, 2023

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.